Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Oscier

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalPaul Moreton, Ben Kennedy, Guy Lucas, et al.
Molecular & Cellular Proteomics : MCP|January 26, 2018
Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome DysregulationHarvey E Johnston, Matthew J Carter, Marta Larrayoz, et al.
British Journal of Haematology|October 13, 2012
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemiaDavid Oscier, Claire Dearden, Efrem Eren, et al.
Haematologica|May 20, 2017
Clinical and diagnostic relevance of <i>NOTCH2</i>-and <i>KLF2</i>-mutations in splenic marginal zone lymphomaYolanda Campos-Martín, Nerea Martínez, Azahara Martínez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2007
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletionBelinda Austen, Anna Skowronska, Claire Baker, et al.
Briefings in Bioinformatics|August 30, 2014
Exome sequence read depth methods for identifying copy number changesLatha Kadalayil, Sajjad Rafiq, Matthew J J Rose-Zerilli, et al.
Blood|December 8, 2005
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)Sarah J Richardson, Christine Matthews, Mark A Catherwood, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trialAnna Skowronska, Anton Parker, Gulshanara Ahmed, et al.
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalPaul Moreton, Ben Kennedy, Guy Lucas, et al.
Molecular & Cellular Proteomics : MCP|January 26, 2018
Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome DysregulationHarvey E Johnston, Matthew J Carter, Marta Larrayoz, et al.
British Journal of Haematology|October 13, 2012
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemiaDavid Oscier, Claire Dearden, Efrem Eren, et al.
Haematologica|May 20, 2017
Clinical and diagnostic relevance of <i>NOTCH2</i>-and <i>KLF2</i>-mutations in splenic marginal zone lymphomaYolanda Campos-Martín, Nerea Martínez, Azahara Martínez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2007
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletionBelinda Austen, Anna Skowronska, Claire Baker, et al.
Briefings in Bioinformatics|August 30, 2014
Exome sequence read depth methods for identifying copy number changesLatha Kadalayil, Sajjad Rafiq, Matthew J J Rose-Zerilli, et al.
Blood|December 8, 2005
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)Sarah J Richardson, Christine Matthews, Mark A Catherwood, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trialAnna Skowronska, Anton Parker, Gulshanara Ahmed, et al.
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Pageof 10